PDF
File
Kurs & Likviditet
Beskrivning
| Land | Danmark |
|---|---|
| Lista | First North Denmark |
| Sektor | Hälsovård |
| Industri | Vård & Omsorg |
- The Brain+ series TO 2 warrant exercise and directed share issue have been registered with the Danish Business Authority (Danish: Erhvervsstyrelsen)
- Interim shares (Danish: IA/midlertidig aktie) from the warrant exercise will be converted into common Brain+ shares (ISIN DK0061670205) and, following conversion, together with shares from the directed issue commence trading on Nasdaq First North Copenhagen on 30 October 2023
Copenhagen, Denmark, 24 October2023 - Brain+ A/S (Nasdaq First North: BRAINP)
Last week, Brain+ A/S ("Brain+" or "the Company") announced the outcome of the exercise period of its warrants of series TO 2 (the "Warrants"), which were issued in connection with the Company's unit rights issue in May 2023. In connection with the Warrant exercise, the Company also carried out a directed issue to guarantors of the Warrant exercise (the "Directed Issue"). The Warrant exercise and the Directed Issue has now been registered with the Danish Business Authority.
After the completion and registration of the Warrant exercise and the Directed Issue with the Danish Business Authority, the number of shares in Brain+ has increased by 21,199,564 shares, from 44,262,866 to 65,462,430 shares, and the Company's nominal share capital has increased by DKK 2,119,956.40, from DKK 4,426,286.60 to DKK 6,546,243.00.
The conversion from interim shares issued based on the Warrant exercise to common shares in Brain+ with the permanent ISIN DK0061670205, will be made on 31 October 2023. Application has been made to Nasdaq Copenhagen A/S for the new shares in the permanent ISIN to be admitted to trading on Nasdaq First North Growth Market Denmark. It is expected that the first day of trading of the new shares will be on 30 October 2023.
Advisors
In connection with the unit rights issue including the issue and exercise of warrants of series TO 2, Sedermera Corporate Finance AB and Gemstone Capital A/S act as financial advisors to Brain+. Markets & Corporate Law Nordic AB act as legal advisor. Nordic Issuing AB is the issuing agent.
For more information about the warrant exercise, please contact:
Sedermera Corporate Finance AB
Phone: +46 (0) 40 615 14 10
E-mail: cf@sedermera.se
www.sedermera.se
Gemstone Capital A/S
Phone: +45 33 22 07 00
E-mail: sh@gemstonecapital.com
www.gemstonecapital.com
For more information about Brain+, please contact:
Kim Baden-Kristensen, CEO
Phone: +45 31 39 33 17
E-mail: kim@brain-plus.com
www.brain-plus.com
Certified Adviser
Keswick Global AG
Phone: +43 1 740 408 045
E-mail: info@keswickglobal.com